Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1β converting enzyme (ICE) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4233-4236

  Soper, David L ^a   Sheville, Justin ^a   O'Neil, Steven V ^a   Wang, Yili ^a   Laufersweiler, Michael C ^a   Oppong, Kofi A ^a   Wos, John A ^a   Ellis, Christopher D ^a   Fancher, Amy N ^a   Lu, Wei ^a   Suchanek, Maureen K ^a   Wang, Richard L ^a   De, Biswanath ^a   Demuth Jr , Thomas P ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

ICE; Inhibitor; Interleukin 1 converting enzyme; Peptidomimetic scaffold

Indexed keywords

AMIDE; CASPASE 3; CASPASE 8; CYSTEINE PROTEINASE; ENZYME INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR;

ARTICLE; CELL ASSAY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50;

AMIDES; AMINOIMIDAZOLE CARBOXAMIDE; CASPASE 1; CASPASE 8; CASPASES; CHEMISTRY, PHARMACEUTICAL; CYSTEINE ENDOPEPTIDASES; DRUG INDUSTRY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL;

EID: 33745684871     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.076     Document Type: Article

References (23)

1. Pelletier J.-P., DiBattistal J.A., Roughley P., McCollum R., and Martel-Pelletier J. In: Moskowitz R.W. (Ed). Osteoarthritis (1993), W. B. Saunders Company, Philadelphia, Pennsylvania 545-568
2. Fernandez-Madrid F., Karvonen R.L., Teitge R.A., Miller P.R., and Negendank W.G. J. Magn. Reson. Imaging 12 (1994) 703
3. Black R.A., Kronheim S.R., Cantrell M., Deeley M.C., March C.J., Prickett K.S., Wignall J., Conlon P.J., Cosman D., Hopp T.P., and Mochizuki D.Y. J. Biol. Chem. 263 (1988) 9437
4. Kobayashi Y., Ichijo Y., Nagatake H., Watanabe N., Nishizawa K., and Goto M. Biochem. Biophys. Res. Commun. 199 (1994) 1035
5. Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., Miller D.K., Molieaux S.M., Weidner J.R., Aunins J., Elliston K.O., Ayala J.M., Casano F.J., Chin J., Ding G.J.-F., Egger L.A., Gaffney E.P., Limjuco G., Palyha O.C., Raju S.M., Rolando A.M., Salley J.P., Yamin T.-T., Lee T.D., Shively J.E., MacCross M., Mumford R.A., Schmidt J.A., and Tocci M.J. Nature 356 (1992) 768
6. Thornberry N.A., Peterson E.P., Zhao J.J., Howard A.D., Griffin P.R., and Chapman K.T. Biochemistry 33 (1992) 3934
7. For reviews of ICE inhibitors, see:. Talanian R.V., Brady K.D., and Cryns V.L. J. Med. Chem. 43 (2000) 3351
8. Ashwell S. Expert Opin. Ther. Patents 11 (2001) 1593
9. Dolle R.E., Prasad C.V.C., Prouty C.P., Salvino J.M., Awad M.M.A., Schmidt S.J., Hoyer D., Ross T.M., Graybill T.L., Speier G.J., Uhl J., Miller B.E., Helaszek C.T., and Ator M.A. J. Med. Chem. 40 (1997) 1941
10. Rudolphi K., Gerwin N., Verzijl N., Van der Kraan P., and Van den Berg W. Osteoarthritis Cartilage 11 (2003) 738
11. Azapeptides have long been used as dipeptide isosteres for enzyme inhibitors, including for example. Greenlee W.J., Thorsett E.D., Springer J.P., and Patchett A.A. Biochem. Biophys. Res. Commun. 122 (1984) 791
12. Gante J. Synthesis (1989) 405
13. Graybill T.L., Dolle R.E., Helaszek C.T., Ator M.A., and Strasters J. Bioorg. Med. Chem. Lett. 5 (1995) 1197
14. Faessler A., Bold G., Capraro H.-G., Cozens R., Mestan J., Poncioni B., Roesel J., Tintelnot-Blomley M., and Lang M. J. Med. Chem. 39 (1996) 3203;
15. James K.E., Asgian J.L., Li Z., Ekici O.D., Rubin J.R., Mikolajczyk J., Salvesen G.S., and Powers J.C. J. Med. Chem. 47 (2004) 1553
16. Dmowski W., and Wolniewicz A. J. Fluorine Chem. 102 (2000) 141-146
17. 3OD): δ 24.91, 33.67, 34.82, 61.54, 105.05, 124.66, 125.37, 125.83, 126.45, 126.98, 128.19, 130.53, 131.04, 131.85, 133.93, 173.19. MS (ESI): m/e = 426.14 (M+H).
18. Batchelor, M. J.; Bebbington, D.; Bemis, G. W.; Fridman, W. H.; Gillespie, R. J.; Golec, J. M. C.; Gu, Y.; Lauffer, D. J.; Livingston, D. J.; Matharu, S. S.; Mullican, M. D.; Murcko, M. A.; Murdoch, R.; Nyce, P. L.; Robidoux, A. L. C.; Su, M.; Wannamaker, M.; Wilson, K. P.; Zelle, R. E. PCT Intl. Appl. WO 9722619, 1997.
19. 0 was the initial velocity in the absence of inhibitor.
20. 6/mL in RPMI 1640 medium from Gibco BRL) was plated in 96-well plates, incubated with or without compounds (administered as solutions in DMSO, such that test concentrations ranged from 1 nM to 10 μM) for 15 min, and then stimulated with LPS (1 μg/mL) for a total of 4 h. Cells were centrifuged and the conditioned media were collected to quantify the release of IL-1β by an ELISA measurement according to the manufacturer's instructions (R&D Systems, catalog number DLB50) or stored at -20 °C for future use.
21. van Oers N.S., and Chen Z.J. Science 308 (2005) 65
22. Oppong K.A., Ellis C.D., Laufersweiler M.C., O'Neil S.V., Wang Y., Soper D.L., Baize M.W., Wos J.A., De B., Bosch G.K., Fancher A.N., Lu W., Suchanek M.K., Wang R.L., and Demuth Jr. T.P. Bioorg. Med. Chem. Lett. 15 (2005) 4291
23. Ellis, C. D.; Oppong, K. A.; Laufersweiler, M. C.; O'Neil, S. V.; Soper, D. L.; Wang, Y.; Wos, J. A.; Fancher, A. N.; Lu, W.; Suchanek, M. K.; Wang, R. L; De, B. 29th National Medicinal Chemistry Symposium, Madison, WI, June 2004, Abstract 110.